Skip to main content
SpringerLink
Log in

Nebenwirkungen der CAR-T-Zell-Therapie

Diagnostik und Therapie CAR-T-Zell-spezifischer Toxizitäten

  • Supportivtherapie
  • AGSMO-Fortbildung
  • Published:
Im Fokus Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. European Medicines Agency Product information: Yescarta.https://www.ema.europa.eu/en/documents/product-information/yescarta-epar-product-information_en.pdf, abgerufen am: 25.09.2020

  2. European Medicines Agency Product information: Kymriah.https://www.ema.europa.eu/en/documents/product-information/kymriah-epar-product-information_en.pdf; aufgerufen am: 25.09.2020

  3. DGHO (2020). CAR-T-Zelltherapie: Qualitätsgesicherte Durchführung in Deutschland- Stand 5/2020.https://www.dgho.de/publikationen/stellungnahmen/gute-aerztliche-praxis/car-t-zelltherapie/car-t-zellen-status-20200722.pdf, aufgerufen am: 25.09.2020

  4. Wang M et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020; 382(14):1331-42

  5. Raje N et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019;380:1726-37

  6. https://clinicaltrials.gov/

  7. Schubert ML et al. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BB zeta retroviral vector: a unicentre phase I/II clinical trial protocol. BMJ Open. 2019; 9(5):e026644

  8. Lee DW et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95

  9. Varadarajan I, Lee DW. Management of T-Cell Engaging Immunotherapy Complications. The Cancer Journal. 2019;25(3):223-20

  10. Neelapu SS et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018; 15(1):47-62

  11. Porter D et al. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11(1):35

  12. Lee DW et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019; 25(4): 625-38

  13. Riegler LL et al. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther Clin Risk Manag. 2019;15:323-35

  14. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8(9):1237-47

  15. Kang S et al. Targeting Interleukin-6 Signaling in Clinic. Immunity. 2019; 50(4):1007-23

  16. Neelapu SS et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26):2531-44

  17. Santomasso BD et al. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer Discov. 2018;8(8):958-71

  18. Hunter BD, Jacobson CA. CAR T-cell associated neurotoxicity: Mechanisms, clinicopathologic correlates, and future directions. J Natl Cancer Inst. 2019;111(7):646-54

  19. Gust J et al. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov. 2017;7(12):1404-19

  20. Gust J et al. Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies. CNS Drugs. 2018;32(12):1091-101

  21. Fried S et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant;2019;54(10):1643-50

  22. Yakoub-Agha I et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020;105(2):297-316

  23. Schubert ML et al. Feasibility and safety of CD19 CAR T cell treatment for B-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020; S1083-8791(20):30258-5

  24. Hill JA et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018;131(1):121-30

  25. Myers RM et al. Inpatient and Intensive Care Unit Resource Utilization after CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy (CART19) for Pediatric Acute Lymphoblastic Leukemia (ALL). Biol Blood Marrow Transplant. 2020;26:S202-3

  26. Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol. 2019;37(suppl_1):48-52

Download references

Author information

Authors and Affiliations

  1. Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany

    Maria-Luisa Schubert,  Karin Jordan,  Carsten Müller-Tidow &  Peter Dreger

Authors
  1. Maria-Luisa Schubert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karin Jordan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carsten Müller-Tidow
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Dreger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria-Luisa Schubert.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schubert, ML., Jordan, K., Müller-Tidow, C. et al. Diagnostik und Therapie CAR-T-Zell-spezifischer Toxizitäten. Im Fokus Onkologie 23, 32–37 (2020). https://doi.org/10.1007/s15015-020-2557-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-020-2557-1

Search

Navigation